Intravesical Instillation Treatment of Non-muscle-invasive Bladder Cancer

European Urology, Supplements

Volumn 8, Issue 7, 2009, Pages 549-555

  Braasch, Matthew R ^a   Böhle, Andreas ^b   O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b HELIOS AGNES KARLL HOSPITAL   (Germany)

Author keywords

Bladder cancer; Chemotherapy; Immunotherapy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; DOCETAXEL; GEMCITABINE; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PLACEBO; PRULIFLOXACIN; SPASMOLYTIC AGENT; VALRUBICIN;

ANAPHYLAXIS; ARTHRALGIA; BACTERIAL CYSTITIS; BLADDER CANCER; BLADDER CONTRACTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; CHILL; CLINICAL TRIAL; CYSTECTOMY; CYSTITIS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EPIDIDYMITIS; FEVER; FLU LIKE SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEMATURIA; HEPATITIS; HIGH RISK POPULATION; HUMAN; HYPERTHERMIC THERAPY; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON MUSCLE INVASION BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PHOTODYNAMIC THERAPY; PNEUMONIA; PRIORITY JOURNAL; PROSTATITIS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TUMOR VOLUME; URETHRITIS;

EID: 67651014416     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.06.009     Document Type: Review

References (51)

1. Jones J.S., and Campbell S.C. Non-muscle-invasive bladder cancer (Ta, T1, CIS). In: Wein A.J., Kavoussi L.R., Novick A.C., et al. (Eds). Campbell's Urology. ed. 9 (2007), WB Saunders, Philadelphia, PA 2447-2467
2. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
3. Jakse G., Algaba F., Malmström P.-U., and Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol 45 (2004) 539-546
4. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178 (2007) 2314-2330
5. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
6. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
7. van der Meijden A.P.M., Sylvester R., Oosterlinck W., et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48 (2005) 363-371
8. Sylvester R.J., van der Meijden A.P., Witjes J.A., and Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86-92
9. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
10. O'Donnell M.A., and Böhle A. Treatment options for BCG failures. World J Urol 24 (2006) 481-487
11. van der Meijden A.P.M., Sylvester R.J., Oosterlinck W., Hoeltl W., Bono A.V., and for the EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44 (2003) 429-434
12. Losa A., Hurle R., and Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 163 (2000) 68-72
13. Lamm D.L., Stogdill V.D., Stogdill B.J., and Crispen R.G. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135 (1986) 272-274
14. Martínez-Piñeiro J.A., Flores N., Isorna S., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680
15. Martínez-Piñeiro J.A., Martínez-Piñeiro L., Solsona E., et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247
16. Ojea A., Nogueira J.L., Solsona E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
17. Bassi P., Spinadin R., Carando R., Balta G., and Pagano F. Modified induction course: a solution to side-effects?. Eur Urol 37 Suppl 1 (2000) 31-32
18. Andius P., Fehrling M., and Holmäng S. Intravesical bacillus Calmette-Guérin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 96 (2005) 1290-1293
19. Colombel M., Saint F., Chopin D., Malavaud B., Nicolas L., and Rischmann P. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176 (2006) 935-939
20. Damiano R, De Sio M, Quarto G, et al. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guerin-induced toxicity? BJU Int. In press.
21. Herr H.W., Badalament R.A., Amato D.A., Laudone V.P., Fair W.R., and Whitmore Jr. W.F. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 141 (1989) 22-29
22. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
23. Fernandez-Gomez J., Solsona E., Unda M., et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53 (2008) 992-1002
24. Solsona E., Iborra I., Dumont R., Rubio-Briones J., and Casanova J. Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000) 685-689
25. Lockyer C.R.W., Sedgwick J.E.C., and Gillatt D.A. Beware the BCG failures: a review of one institution's results. Eur Urol 42 (2002) 542-546
26. Quek M.L., Stein J.P., Nichols P.W., et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174 (2005) 103-106
27. Kamat A.M., Dinney C.P., Gee J.R., et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110 (2007) 62-67
28. Palou J., Baniel J., Klotz L., et al. Urothelial carcinoma of the prostate. Urology 69 Suppl 1 (2007) 50-61
29. Shen S.S., Lerner S.P., Muezzinoglu B., Truong L.D., Amiel G., and Wheeler T.M. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol 37 (2006) 726-734
30. Huguet J., Crego M., Sabaté S., Salvador J., Palou J., and Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48 (2005) 53-59
31. Taylor J.H., Davis J., and Schellhammer P. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. Clin Genitourin Cancer 5 (2007) 386-389
32. Hurle R., Losa A., Manzetti A., and Lembo A. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54 (1999) 258-263
33. Joudi F.N., Smith B.J., and O'Donnell M.A. National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348
34. Kipp B.R., Karnes R.J., Brankley S.M., et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173 (2005) 401-404
35. Mengual L., Marín-Aguilera M., Ribal M.J., et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy. Eur Urol 52 (2007) 752-759
36. Lamm D.L., and Griffith J.G. Intravesical therapy: does it affect the natural history of superficial bladder cancer?. Semin Urol 10 (1992) 39-44
37. Thalmann G.N., Markwalder R., Shahin O., Burkhard F.C., Hochreiter W.W., and Studer U.E. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?. J Urol 172 (2004) 70-75
38. Bui T.T., and Schellhammer P.F. Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49 (1997) 687-691
39. Luo Y., Chen X., Downs T.M., DeWolf W.C., and O'Donnell M.A. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 162 (1999) 2399-2405
40. Belldegrun A.S., Franklin J.R., O'Donnell M.A., et al. Superficial bladder cancer: the role of interferon-alpha. J Urol 159 (1998) 1793-1801
41. Punnen S.P., Chin J.L., and Jewett M.A. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol 10 (2003) 1790-1795
42. O'Donnell M.A., Krohn J., and DeWolf W.C. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 166 (2001) 1300-1305
43. Lam J.S., Benson M.C., O'Donnell M.A., et al. Bacillus Calmette-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21 (2003) 354-360
44. Maymí J.L., and O'Donnell M.A. for the National BCG/Interferon Investigator Group. Factors affecting response to BCG plus interferon in patients with urothelial carcinoma in situ. J Urol 173 Suppl 4 (2005) 248 abstract 918
45. Lamm D.L., and O'Donnell M.A. Multicenter randomized comparison of BCG with or without alfa 2b interferon (IFN) and Oncovite (Onc) versus recommended daily allowance (RDA) vitamins during induction and extended 3-week maintenance. J Urol 179 Suppl 4 (2008) 584 abstract 1705
46. O'Donnell M.A., Lilli K., and Leopold C. National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172 (2004) 888-893
47. Malmström P.U., Wijkström H., Lundholm C., Wester K., Busch C., and Norlén B.J. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161 (1999) 1124-1127
48. Steinberg G., Bahnson R., Brosman S., Middleton R., Wajsman Z., and Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163 (2000) 761-767
49. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24 (2006) 2729-2734
50. Maymí J.L., Saltsgaver N., and O'Donnell M.A. Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer. J Urol 174 Suppl 4 (2006) 271 abstract 840
51. Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU Int. In press.